Overview

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Status:
RECRUITING
Trial end date:
2027-03-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
Phase:
PHASE3
Details
Lead Sponsor:
Amgen
Treatments:
pembrolizumab